JPWO2021102569A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021102569A5 JPWO2021102569A5 JP2022530212A JP2022530212A JPWO2021102569A5 JP WO2021102569 A5 JPWO2021102569 A5 JP WO2021102569A5 JP 2022530212 A JP2022530212 A JP 2022530212A JP 2022530212 A JP2022530212 A JP 2022530212A JP WO2021102569 A5 JPWO2021102569 A5 JP WO2021102569A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- dimethyloct
- dien
- diol
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 7
- -1 C 1 -C 4 alkyl Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 229910052796 boron Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 2
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- DDLQQMREUUSOGZ-UHFFFAOYSA-N CC(=CCC1=C(C(=C(C=C1O)CCCCC)C1=CC(=CC=C1)N1CCOCC1)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C(=C(C=C1O)CCCCC)C1=CC(=CC=C1)N1CCOCC1)O)CCC=C(C)C DDLQQMREUUSOGZ-UHFFFAOYSA-N 0.000 claims 1
- RSYUDDBINVFQEL-UHFFFAOYSA-N CC(=CCC1=C(C(=C(C=C1O)CCCCC)C1=CC=C(C=C1)C=1C=NC=CC=1)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C(=C(C=C1O)CCCCC)C1=CC=C(C=C1)C=1C=NC=CC=1)O)CCC=C(C)C RSYUDDBINVFQEL-UHFFFAOYSA-N 0.000 claims 1
- KIAFFAWXBCQDNV-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CC(=NC=C1)C)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CC(=NC=C1)C)CCCCC)O)CCC=C(C)C KIAFFAWXBCQDNV-UHFFFAOYSA-N 0.000 claims 1
- JDHCGJAZOCLEJS-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CC=NC=C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CC=NC=C1)CCCCC)O)CCC=C(C)C JDHCGJAZOCLEJS-UHFFFAOYSA-N 0.000 claims 1
- VLSLENQGLMRDIX-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CC=NN1C)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CC=NN1C)CCCCC)O)CCC=C(C)C VLSLENQGLMRDIX-UHFFFAOYSA-N 0.000 claims 1
- VWZOLGJPQYSNMD-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CC=NO1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CC=NO1)CCCCC)O)CCC=C(C)C VWZOLGJPQYSNMD-UHFFFAOYSA-N 0.000 claims 1
- YTTKVZYOPALESJ-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CN=CS1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CN=CS1)CCCCC)O)CCC=C(C)C YTTKVZYOPALESJ-UHFFFAOYSA-N 0.000 claims 1
- CCZJEEBOTGQJFU-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CNC=C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CNC=C1)CCCCC)O)CCC=C(C)C CCZJEEBOTGQJFU-UHFFFAOYSA-N 0.000 claims 1
- VCFGXXIVCRZATJ-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CSC=C1)CCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CSC=C1)CCC)O)CCC=C(C)C VCFGXXIVCRZATJ-UHFFFAOYSA-N 0.000 claims 1
- DZEARACRYRPRTE-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=CSC=C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=CSC=C1)CCCCC)O)CCC=C(C)C DZEARACRYRPRTE-UHFFFAOYSA-N 0.000 claims 1
- WIGOVCAGFYAYBV-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NC(=NO1)C)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NC(=NO1)C)CCCCC)O)CCC=C(C)C WIGOVCAGFYAYBV-UHFFFAOYSA-N 0.000 claims 1
- MBUUDQRVUNXLCW-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NC=CC=C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NC=CC=C1)CCCCC)O)CCC=C(C)C MBUUDQRVUNXLCW-UHFFFAOYSA-N 0.000 claims 1
- AQYYNEHLAOKPPT-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NC=CC=N1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NC=CC=N1)CCCCC)O)CCC=C(C)C AQYYNEHLAOKPPT-UHFFFAOYSA-N 0.000 claims 1
- KLLNSTVNLNYTBN-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NC=CN=C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NC=CN=C1)CCCCC)O)CCC=C(C)C KLLNSTVNLNYTBN-UHFFFAOYSA-N 0.000 claims 1
- WNVNCHKCNQZMGX-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NC=NC=C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NC=NC=C1)CCCCC)O)CCC=C(C)C WNVNCHKCNQZMGX-UHFFFAOYSA-N 0.000 claims 1
- NBQASIYTEFJKAI-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NN=NN1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NN=NN1)CCCCC)O)CCC=C(C)C NBQASIYTEFJKAI-UHFFFAOYSA-N 0.000 claims 1
- XDIQUPGGGLHWTD-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1=NOC(=N1)C)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1=NOC(=N1)C)CCCCC)O)CCC=C(C)C XDIQUPGGGLHWTD-UHFFFAOYSA-N 0.000 claims 1
- YESAOUUIIQEUFH-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1COC1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1COC1)CCCCC)O)CCC=C(C)C YESAOUUIIQEUFH-UHFFFAOYSA-N 0.000 claims 1
- BLOASJBFHMHUAI-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1NC2=CC=CC=C2C1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1NC2=CC=CC=C2C1)CCCCC)O)CCC=C(C)C BLOASJBFHMHUAI-UHFFFAOYSA-N 0.000 claims 1
- LLKNOVFWVOKWPX-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1OC1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1OC1)CCCCC)O)CCC=C(C)C LLKNOVFWVOKWPX-UHFFFAOYSA-N 0.000 claims 1
- FYLNOLOEIFUXKZ-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C1OCC1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C1OCC1)CCCCC)O)CCC=C(C)C FYLNOLOEIFUXKZ-UHFFFAOYSA-N 0.000 claims 1
- SBGUDYQPKNUFQO-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1C=C2C=NNC2=CC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1C=C2C=NNC2=CC=1)CCCCC)O)CCC=C(C)C SBGUDYQPKNUFQO-UHFFFAOYSA-N 0.000 claims 1
- NGYJTENVAAHYDM-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1C=C2N=CC=NC2=CC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1C=C2N=CC=NC2=CC=1)CCCCC)O)CCC=C(C)C NGYJTENVAAHYDM-UHFFFAOYSA-N 0.000 claims 1
- VALPKSAODLHGMI-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1C=NC2=CC=CC=C2C=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1C=NC2=CC=CC=C2C=1)CCCCC)O)CCC=C(C)C VALPKSAODLHGMI-UHFFFAOYSA-N 0.000 claims 1
- HAHYBDUVMWHWKO-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1C=NC=CC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1C=NC=CC=1)CCCCC)O)CCC=C(C)C HAHYBDUVMWHWKO-UHFFFAOYSA-N 0.000 claims 1
- KGVNTTWFTIXQKZ-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1C=NC=NC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1C=NC=NC=1)CCCCC)O)CCC=C(C)C KGVNTTWFTIXQKZ-UHFFFAOYSA-N 0.000 claims 1
- DGIHNASYURAKLD-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1C=NNC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1C=NNC=1)CCCCC)O)CCC=C(C)C DGIHNASYURAKLD-UHFFFAOYSA-N 0.000 claims 1
- MEZMUWARMCMUSU-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1N=CSC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1N=CSC=1)CCCCC)O)CCC=C(C)C MEZMUWARMCMUSU-UHFFFAOYSA-N 0.000 claims 1
- KIDCADSEOTXWID-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1NC2=CC=CC=C2C=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1NC2=CC=CC=C2C=1)CCCCC)O)CCC=C(C)C KIDCADSEOTXWID-UHFFFAOYSA-N 0.000 claims 1
- KVHXXDBBQBCPBL-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1NC2=NC=NC=C2N=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1NC2=NC=NC=C2N=1)CCCCC)O)CCC=C(C)C KVHXXDBBQBCPBL-UHFFFAOYSA-N 0.000 claims 1
- KKNBCCPXGDQHRB-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1NC=CC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1NC=CC=1)CCCCC)O)CCC=C(C)C KKNBCCPXGDQHRB-UHFFFAOYSA-N 0.000 claims 1
- AXARRVLNRLCDHW-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1OC=CC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1OC=CC=1)CCCCC)O)CCC=C(C)C AXARRVLNRLCDHW-UHFFFAOYSA-N 0.000 claims 1
- LRYUSDZRGPJVRV-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1SC=C(C=1)C)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1SC=C(C=1)C)CCCCC)O)CCC=C(C)C LRYUSDZRGPJVRV-UHFFFAOYSA-N 0.000 claims 1
- SLHXHKGAUFQKKY-UHFFFAOYSA-N CC(=CCC1=C(C=C(C(=C1O)C=1SC=CC=1)CCCCC)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C=C(C(=C1O)C=1SC=CC=1)CCCCC)O)CCC=C(C)C SLHXHKGAUFQKKY-UHFFFAOYSA-N 0.000 claims 1
- UFUDOAYVJBKTCJ-UHFFFAOYSA-N CC1=NOC(=C1C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O)C Chemical compound CC1=NOC(=C1C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O)C UFUDOAYVJBKTCJ-UHFFFAOYSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 102100033061 G-protein coupled receptor 55 Human genes 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 claims 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 1
- 101000829761 Homo sapiens N-arachidonyl glycine receptor Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 102100023414 N-arachidonyl glycine receptor Human genes 0.000 claims 1
- AUFBEUBRLUTEPX-UHFFFAOYSA-N N1(CC1)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O Chemical compound N1(CC1)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O AUFBEUBRLUTEPX-UHFFFAOYSA-N 0.000 claims 1
- CZIKFIZRESCCSO-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O Chemical compound N1C(=NC2=C1C=CC=C2)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O CZIKFIZRESCCSO-UHFFFAOYSA-N 0.000 claims 1
- QGZARLUJTCWAFH-UHFFFAOYSA-N N1C(C1)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O Chemical compound N1C(C1)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O QGZARLUJTCWAFH-UHFFFAOYSA-N 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- KTPJBDNSRKBRAJ-UHFFFAOYSA-N O1C(=CC2=C1C=CC=C2)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O Chemical compound O1C(=CC2=C1C=CC=C2)C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O KTPJBDNSRKBRAJ-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- KNQJYXNRILQPIP-UHFFFAOYSA-N S1C2=C(C=C1C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O)C=CC=C2 Chemical compound S1C2=C(C=C1C1=C(C(=C(C=C1CCCCC)O)CC=C(CCC=C(C)C)C)O)C=CC=C2 KNQJYXNRILQPIP-UHFFFAOYSA-N 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102000003566 TRPV1 Human genes 0.000 claims 1
- 206010043903 Tobacco abuse Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 101150016206 Trpv1 gene Proteins 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 108020001612 μ-opioid receptors Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940568P | 2019-11-26 | 2019-11-26 | |
| US62/940,568 | 2019-11-26 | ||
| US202063076742P | 2020-09-10 | 2020-09-10 | |
| US63/076,742 | 2020-09-10 | ||
| US202063104927P | 2020-10-23 | 2020-10-23 | |
| US63/104,927 | 2020-10-23 | ||
| PCT/CA2020/051609 WO2021102569A1 (en) | 2019-11-26 | 2020-11-25 | Cannabinoid derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503331A JP2023503331A (ja) | 2023-01-27 |
| JPWO2021102569A5 true JPWO2021102569A5 (https=) | 2023-11-22 |
| JP2023503331A5 JP2023503331A5 (https=) | 2023-11-22 |
Family
ID=76128641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530212A Pending JP2023503331A (ja) | 2019-11-26 | 2020-11-25 | カンナビノイド誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230122510A1 (https=) |
| EP (1) | EP4065568A4 (https=) |
| JP (1) | JP2023503331A (https=) |
| WO (1) | WO2021102569A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3997098A4 (en) | 2019-07-12 | 2023-10-11 | Canopy Growth Corporation | CANNABINOIDS DERIVATIVES |
| WO2021007663A1 (en) | 2019-07-12 | 2021-01-21 | Canopy Growth Corporation | Cannabinoid derivatives |
| JP2022540586A (ja) | 2019-07-12 | 2022-09-16 | キャノピー グロウス コーポレイション | カンナビノイド誘導体 |
| WO2021062559A1 (en) | 2019-10-02 | 2021-04-08 | Canopy Growth Corporation | Cannabinoid derivatives |
| EP4065554A4 (en) | 2019-11-26 | 2024-01-10 | Canopy Growth Corporation | CANNABIGEROL DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| WO2021245672A1 (en) * | 2020-06-03 | 2021-12-09 | Epm (Ip), Inc. | Cannabigerolic acid (cbga) derivatives and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2744882A (en) * | 1949-01-26 | 1956-05-08 | Union Carbide & Carbon Corp | Unsymmetrical diphenylol methanes |
| US6737439B2 (en) * | 2001-08-07 | 2004-05-18 | The Board Of Trustees Of The University Of Illinois | Aromatase inhibitors from Broussonetia papyrifera |
| WO2007139887A2 (en) * | 2006-05-22 | 2007-12-06 | Cargill, Incorporated | Methods for treating bone or joint inflammation |
| GB2450493A (en) * | 2007-06-25 | 2008-12-31 | Gw Pharma Ltd | Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors |
| JP2011140477A (ja) * | 2009-03-04 | 2011-07-21 | Tohoku Univ | Ｃｂ１受容体アゴニスト |
| US9095598B2 (en) * | 2010-12-28 | 2015-08-04 | The Board Of Trustees Of The University Of Arkansas | Stilbenoid derivatives and their uses |
| PL223441B1 (pl) * | 2013-09-27 | 2016-10-31 | Univ Przyrodniczy We Wrocławiu | 4'-O-β-D-glukopiranozylo-4,2'-dihydroksy-6'-metoksy-3'-prenylo-α,β-dihydrochalkon oraz sposób jego wytwarzania |
| CA3019890A1 (en) * | 2016-04-04 | 2017-10-12 | Teewinot Technologies Limited | Bioenzymatic synthesis of tetrahydrocannabivarin (thc-v), cannabinol (cbn), and cannabivarin (cbv) and their use as therapeutic agents |
| US20190321355A1 (en) * | 2016-12-15 | 2019-10-24 | Sharon Anavi-Goffer | Treatment of mental, movement and behavioral disorders |
| CN107987047B (zh) * | 2017-12-22 | 2020-03-20 | 成都普思生物科技股份有限公司 | 一种从桑白皮中提取的牻牛儿基黄酮化合物及其方法和应用 |
| JP2023503330A (ja) * | 2019-11-26 | 2023-01-27 | キャノピー グロウス コーポレイション | カンナビノイド誘導体 |
-
2020
- 2020-11-25 US US17/780,054 patent/US20230122510A1/en not_active Abandoned
- 2020-11-25 EP EP20891431.7A patent/EP4065568A4/en active Pending
- 2020-11-25 JP JP2022530212A patent/JP2023503331A/ja active Pending
- 2020-11-25 WO PCT/CA2020/051609 patent/WO2021102569A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5583694B2 (ja) | Ｃｂ２受容体を調節するピロリジン化合物 | |
| JP5756800B2 (ja) | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 | |
| KR101470659B1 (ko) | 면역조절제로서 피리딘-4-일 유도체 | |
| JP5749162B2 (ja) | Ｃｂ２受容体を調節するスルホン化合物 | |
| JP5820056B2 (ja) | Ｃｅｔｐ阻害剤としてのシクロアルケニルアリール誘導体 | |
| JP2011520884A (ja) | Ｃｂ２受容体を変調するスルホン化合物 | |
| JP2022548028A (ja) | Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物 | |
| CA2849169A1 (en) | Pyrazole carboxamides as janus kinase inhibitors | |
| CN1378541A (zh) | c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂 | |
| JPWO2012102255A1 (ja) | インドール誘導体、またはその薬理学的に許容される塩 | |
| EP2462139B1 (en) | Sphingosine-1-phosphate receptor agonists | |
| KR20100122489A (ko) | 아제티딘-유도 화합물, 그의 제조 방법 및 그의 치료학적 용도 | |
| JP2004521863A (ja) | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体 | |
| AU2009220861A1 (en) | Pyridin-2-YL derivatives as immunomodulating agents | |
| JP2010509216A (ja) | ヘテロシクリル置換抗高コレステロール血症化合物 | |
| JPWO2021102569A5 (https=) | ||
| JP5735634B2 (ja) | スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物 | |
| WO2012020738A1 (ja) | 複素環化合物およびその用途 | |
| WO2015160772A1 (en) | Tetrahydro-benzoimidazolyl modulators of tgr5 | |
| JPWO2021007659A5 (https=) | ||
| JPWO2021007661A5 (https=) | ||
| JPWO2021062557A5 (https=) | ||
| HUE026012T2 (en) | 2-methoxy-pyridin-4-yl derivatives | |
| JPWO2021000054A5 (https=) | ||
| CA1335816C (en) | 4-pyridyl-1,3-dioxan-5-ylalkenoic acid derivatives |